ACS Medicinal Chemistry Letters
Letter
ASSOCIATED CONTENT
■
S
* Supporting Information
1
All experimental details, H and 13C spectroscopic data, and
other related material. This material is available free of charge
AUTHOR INFORMATION
■
Corresponding Author
Funding
We acknowledge financial support from the University of
WisconsinMadison Graduate School (Senator Robert
Caldwell Graduate Fellowship to Y.-J.E), the Alfred P. Sloan
Foundation (fellowship to D.B.W.), NIH (grant
1DP2OD008735-01), the Wisconsin Alumni Research Foun-
dation, and the Human Frontiers Science Program (grant
RGY0069/2008-C103).
Notes
The authors declare no competing financial interest.
Figure 2. Divin analogues produced the same cellular phenotype with
Gram-negative bacteria as did 1. This figure shows panels of C.
crescentus CB15N cells treated with different analogues and DMSO
control: (a) 1; (b) 8b; (c) 11c; (d) 11e; (e) 11f; (f) 11g; (g) 11i; (h)
11j; and (i) DMSO.
ACKNOWLEDGMENTS
■
We thank Regan Thomson for insightful comments.
REFERENCES
■
(1) Silver, L. L. Challenges of antibacterial discovery. Clin. Microbiol.
Rev. 2011, 24, 71−109.
Table 3. MIC of 1 and 11j against Various Pathogenic
a
Strains of Bacteria; MIC Is Expressed As μM
(2) Black, M. T.; Stachyra, T.; Platel, D.; Girard, A. M.; Claudon, M.;
Bruneau, J. M.; Miossec, C. Mechanism of action of the antibiotic
NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II
topoisomerases. Antimicrob. Agents Chemother. 2008, 52, 3339−3349.
(3) Bax, B. D.; Chan, P. F.; Eggleston, D. S.; Fosberry, A.; Gentry, D.
R.; Gorrec, F.; Giordano, I.; Hann, M. M.; Hennessy, A.; Hibbs, M.;
Huang, J.; Jones, E.; Jones, J.; Brown, K. K.; Lewis, C. J.; May, E. W.;
Saunders, M. R.; Singh, O.; Spitzfaden, C. E.; Shen, C.; Shillings, A.;
Theobald, A. J.; Wohlkonig, A.; Pearson, N. D.; Gwynn, M. N. Type
IIA topoisomerase inhibition by a new class of antibacterial agents.
Nature 2010, 466, 935−940.
MIC
pathogenic bacteria
1
11J
Morganella morganii
Klebsiella pneumonia
Acinetobacter baumannii
Salmonella typhimurium
Shigella boydii
>50
>50
50
50
50
50
6
>50
50
50
25
25
12
3
Enterobacter aerogenes
Vibrio cholera
(4) Swinney, D. C.; Anthony, J. How were new medicines
discovered? Nat. Rev. Drug Discovery 2011, 10, 507−519.
(5) Lee, J. A.; Uhlik, M. T.; Moxham, C. M.; Tomandl, D.; Sall, D. J.
Modern phenotypic drug discovery is a viable, neoclassic pharma
strategy. J. Med. Chem. 2012, 55, 4527−4530.
a
All strains are clinical isolates.
studies have enabled us to identify three analogues (8b, 11c,
and 11j) with improved solubility and potency. Importantly,
these compounds produce the same phenotype as 1, which
suggests that they share a similar mechanism of action.
Our studies indicate that the 2-hydroxy-1-naphthalenyl
portion of 1 is primarily responsible for its activity and that
alterations and substitution to the benzimidazole ring can
increase its potency. Compounds 11c and 11j were more active
than 1 against E. coli BW25113 ΔtolC, and their solubility was
10- and 4-fold higher than 1 in M8 media, respectively. The
solubility improvement of these analogues will enable us to
pursue the molecular target by isolation and characterization of
spontaneous mutants that display reduced susceptibility to the
compound. More importantly, the SAR results enabled us to
design and synthesize additional analogues that include a
reactive azide group and/or a photoactivated diazirine probe,
which exhibit virtually identical in vivo activity to 1.9,21 We
anticipate that these probes will enable us to identify the
molecular target of 1, and we plan to report the results of these
studies at a later date.
(6) Tally, F. P.; DeBruin, M. F. Development of daptomycin for
gram-positive infections. J. Antimicrob. Chemother. 2000, 46, 523−526.
(7) Hurdle, J. G.; O’Neill, A. J.; Chopra, I.; Lee, R. E. Targeting
bacterial membrane function: an underexploited mechanism for
treating persistent infections. Nat. Rev. Microbiol. 2011, 9, 62−75.
(8) Eun, Y. J.; Foss, M. H.; Kiekebusch, D.; Pauw, D. A.; Westler, W.
M.; Thanbichler, M.; Weibel, D. B. DCAP: a broad-spectrum antibiotic
that targets the cytoplasmic membrane of bacteria. J. Am. Chem. Soc.
2012, 134, 11322−11325.
(9) Eun, Y. J.; Zhou, M.; Kiekebusch, S.; Schlimpert, R. R.; Trivedi,
S.; Bakshi, T. A.; Wahlig, M.; Thanbichler, M.; Weibel, D. B. Divin: a
small molecule inhibitor of bacterial divisome assembly. J. Am. Chem.
Soc. 2013, 135, 9768−9776.
(10) Anderson, D. E.; Kim, M. B.; Moore, J. T.; O’Brien, T. E.; Sorto,
N. A.; Grove, C. I.; Lackner, L. L.; Ames, J. B.; Shaw, J. T. Comparison
of small molecule inhibitors of the bacterial cell division protein FtsZ
and identification of a reliable cross-species inhibitor. ACS Chem. Biol.
2012, 7, 1918−1928.
(11) Foss, M. H.; Eun, Y. J.; Weibel, D. B. Chemical−biological
studies of subcellular organization in bacteria. Biochemistry 2011, 50,
7719−7734.
E
dx.doi.org/10.1021/ml400234x | ACS Med. Chem. Lett. XXXX, XXX, XXX−XXX